The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Eisai's 2012 sales performance.
The deal comes just a few weeks after Biogen and Eisai’s jointly developed Alzheimer’s disease drug was granted traditional approval in the US for use in patients with mild
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Alzheimer’s Association International
Earlier this month, Biogen and Eisai’s Alzheimer’s disease drug Leqembi was granted traditional approval by the US Food and Drug Administration, making it the first and only approved
In a very welcome move, Biogen and Eisai’s Alzheimer’s disease drug has been granted traditional approval by the US Food and Drug Administration (FDA). ... Eisai’s supplemental biologics application for approval under the traditional pathway was
Biogen and Eisai’s Alzheimer’s disease drug has been recommended for traditional approval by a US Food and Drug Administration (FDA) panel of experts. ... Eisai’s supplemental biologics application for approval under the traditional pathway is
No results were found
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...